ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients

Relationship among symptom clusters, quality of life, and treatment-specific optimism in patients with cancer

(2018) Martin Matzka et al.   SUPPORTIVE CARE IN CANCER

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Paul J. Hesketh et al.   JOURNAL OF CLINICAL ONCOLOGY

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

(2016) F. Roila et al.   ANNALS OF ONCOLOGY

Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy

(2016) Paul J. Hesketh et al.   CANCER

Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan

(2016) Kazuo Tamura et al.   International Journal of Clinical Oncology

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

(2016) Rudolph M. Navari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial

(2015) C. Weinstein et al.   ANNALS OF ONCOLOGY

Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study

(2015) F. Roila et al.   ANNALS OF ONCOLOGY

Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients

(2015) Kulthida Rithirangsriroj et al.   GYNECOLOGIC ONCOLOGY

Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin

(2015) Hideaki Yahata et al.   International Journal of Clinical Oncology

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

(2015) Yolanda Escobar et al.   SUPPORTIVE CARE IN CANCER

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

(2015) Rudolph M. Navari   Biomed Research International

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

(2014) M. Aapro et al.   ANNALS OF ONCOLOGY

Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study

(2014) James W. Gilmore et al.   Journal of Oncology Practice

Can Granisetron Injection Used as Primary Prophylaxis Improve the Control of Nausea and Vomiting with Low-Emetogenic Chemotherapy?

(2013) Chan Huan Keat et al.   Asian Pacific Journal of Cancer Prevention

Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study

(2013) Fausto Roila et al.   JOURNAL OF CLINICAL ONCOLOGY

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

(2013) Rudolph M. Navari et al.   SUPPORTIVE CARE IN CANCER

Direct provider feedback to decrease chemotherapy ordering errors: The “gray envelope” initiative

(2012) Katie Bruce et al.   PEDIATRIC BLOOD & CANCER

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting

(2011) Henning Burmeister et al.   SUPPORTIVE CARE IN CANCER